Geron's Minimal Sales Growth May Be Offset by Future Catalysts

jueves, 19 de marzo de 2026, 11:05 am ET1 min de lectura
GERN--

Geron Corporation (GERN) has minimal sales growth but potential catalysts ahead with multiple clinical readouts in 2026. The company's performance with Rytelo (imetelstat) will be a key factor in its future. Despite limited sales growth, GERN has the potential to experience a run-up due to upcoming clinical results.

Geron's Minimal Sales Growth May Be Offset by Future Catalysts

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios